Decoy Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(713) 913-5608Website
www.decoytx.comRevenue
-Stock Symbol
DCOYIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Decoy Therapeutics
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.Explore more
Decoy Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Decoy Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Decoy Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Decoy Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Decoy Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Decoy Therapeutics recently announced quarterly report
Click to see if Decoy Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Decoy Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Decoy Therapeutics
Product Launch: Get notified when Decoy Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Decoy Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Decoy Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Decoy Therapeutics.
Decoy Therapeutics financials insights
Gather financial insights about Decoy Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$1.2M
2026
Stock/Share Issuance
$3.5M
Decoy Therapeutics Tech Stack
A closer look at the technologies used by Decoy Therapeutics
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Governance
Funding
Decoy Therapeutics has secured $3.5 million in Stock Issuance funding. Investors were not disclosed.
Funding
Funding
, according to a recent Form D filing, has secured $1,200,000 in Debt funding.
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Decoy Therapeutics News & Media
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the platform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable...Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia...Decoy Therapeutics Enters Up To $21 Mln PIPE Financing; Stock Surges In Pre-Market
Decoy Therapeutics, Inc. (DCOY), a clinical-stage biotech company, announced it entered into a securities purchase agreement with a single healthcare-focused institutional investor for a private investment in public equity (PIPE).Decoy Therapeutics (NASDAQ: DCOY) lines up $21M milestone-based PIPE funding
Decoy Therapeutics arranges a PIPE with $3.5M upfront and up to $17.5M in milestone warrant proceeds to fund its multi-viral antiviral programs toward clinical trials.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Decoy Therapeutics
Sign Up For FreeTo access detailed company insights
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and... Read More
